KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prophylactic endoscopic pylorus dilatation prior to esophagectomy for esophageal cancer to prevent delayed gastric emptying, study protocol for a placebo-controlled randomized trial (PROPPER trial). PMID 40551220 · Trials · 2025-Jun-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Remote ischaemic preconditioning in cemented hip arthroplasty (the PRINCIPAL study)-randomised controlled trial: study protocol. PMID 40550717 · BMJ Open · 2025-Jun-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small-cell lung cancer better preserves white matter networks compared to conventional PCI. PMID 39718983 · Neuro Oncol · 2025-Jun-21 This is an original randomized phase 3 trial in oncology, but it evaluates radiation techniques (HA-PCI vs PCI) and reports on neurocognitive and imaging endpoints, not a drug intervention or a time-to-event efficacy endpoint (OS, PFS, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Phrenic Nerve Cryotherapy for Preventing Prolonged Air Leak During VATS Lobectomy]. PMID 40640090 · Zhongguo Fei Ai Za Zhi · 2025-Jun-20 The study is a randomized trial in oncology (lung cancer) but fails key eligibility criteria: it is not a Phase III/IIIb or Phase II/III drug trial (the intervention is a procedural cryotherapy during surgery, not a drug), and it does not report a time-to-event efficacy endpoint (primary outcome is complication rate, not survival or progression).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. PMID 40367400 · J Clin Oncol · 2025-Jun-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. PMID 40354592 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. PMID 40334149 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. PMID 40294349 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. PMID 40239133 · J Clin Oncol · 2025-Jun-20 The record describes a randomized trial with a primary time-to-event efficacy endpoint (PFS) and reports formal interim results with HR and median survival times. The phase is not explicitly labeled as 'Phase III' in the provided metadata, but the trial design (multicenter, 109 patients, standard comparator) and definitive interim analysis supporting a conclusion of 'standard initial therapy' are consistent with a Phase III/IIIb definitive trial. Therefore, eligibility is confirmed.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. PMID 40537275 · RMD Open · 2025-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. PMID 40293180 · N Engl J Med · 2025-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. PMID 40202593 · N Engl J Med · 2025-Jun-19 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. PMID 40367619 · Eur J Cancer · 2025-Jun-18 The record is a sub-analysis of the APHINITY trial focusing on BMI and weight changes, not the original primary result report of the randomized trial's efficacy. It is a subgroup/post-hoc analysis, which is excluded per the adjudication rules.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial. PMID 40528226 · Trials · 2025-Jun-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. PMID 40480221 · Cell Rep Med · 2025-Jun-17 The record describes an original, randomized, Phase III oncology trial with drug interventions. However, the primary endpoint is pathological complete response (pCR), a binary categorical outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). There is no signal of Kaplan-Meier analysis or hazard ratios for a time-to-event endpoint in the abstract or metadata. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. PMID 40526078 · Cancer · 2025-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluation of machine-learning models to measure individualized treatment effects from randomized clinical trial data with time-to-event outcomes. PMID 40980764 · ArXiv · 2025-Jun-13 The record describes a methodological study evaluating machine learning models using data from randomized trials, but it is not itself a report of an original randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. It lacks explicit Phase III/IIIb or Phase II/III trial evidence and does not report on a specific drug-containing intervention's efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission from Melanoma: A Randomized Controlled Trial. PMID 40565447 · Healthcare (Basel) · 2025-Jun-13 The study is a randomized controlled trial in human melanoma survivors. It is not a drug intervention trial (evaluates Emotional Freedom Techniques). It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR); outcomes are psychological/wellbeing measures from questionnaires and distress scores. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of Hangeshashinto in delaying grade 2 radiotherapy-induced mucositis development in patients with hypopharyngeal or laryngeal cancer: Preliminary finding of a randomized clinical trial. PMID 40527845 · Medicine (Baltimore) · 2025-Jun-13 The study is an oncology, human, randomized trial with a time-to-event endpoint (Kaplan-Meier) and a drug intervention (herbal medicine). However, it fails the key criterion of being a Phase III/IIIb or Phase II/III trial. The metadata and abstract indicate it is a preliminary, single-center study, with no explicit mention of Phase III. Therefore, it does not meet the eligibility requirement for definitive phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer. PMID 40358364 · Clin Cancer Res · 2025-Jun-13 The study is a randomized Phase II window-of-opportunity study evaluating a biomarker (PARP inhibition) as the primary objective, not a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. PMID 40227186 · Clin Cancer Res · 2025-Jun-13 The study is an oncology randomized trial with drug intervention and reports OS as a co-primary endpoint, but the abstract does not present any OS results (e.g., survival curves, median, HR) – it only reports organ preservation rates. Furthermore, the trial phase is not confirmed as Phase III or definitive; it appears to be a smaller randomized study possibly Phase II. Therefore, it lacks the explicit Phase III/IIIb or Phase II/III designation and the required time-to-event efficacy results for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial. PMID 40192715 · Clin Cancer Res · 2025-Jun-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Effect of electroacupuncture on intestinal function after gastric cancer surgery]. PMID 40518778 · Zhongguo Zhen Jiu · 2025-Jun-12 The study is a randomized trial in oncology (gastric cancer surgery) but does not meet key eligibility criteria: 1) The intervention is electroacupuncture combined with enhanced recovery after surgery (ERAS), not a drug-containing intervention. 2) The primary endpoints are functional recovery metrics (intestinal motility, tolerance to oral intake) and inflammatory markers, not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any analysis with Kaplan-Meier curves or hazard ratios. 3) The trial phase is not specified, but based on the context (post-surgical adjuvant care), it is unlikely to be a Phase III/IIIb or Phase II/III trial of a drug. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Subcutaneous versus intravenous route switch from oral to parenteral morphine in patients with cancer: randomised controlled trial. PMID 40506094 · BMJ Support Palliat Care · 2025-Jun-12 The study is a randomized trial in cancer patients, but it does not meet key eligibility criteria: (1) The intervention compares subcutaneous vs. intravenous administration routes for morphine, not a drug vs. control; (2) The time-to-event endpoints (time to stable infusion rate, time to pain relief) are not standard oncology efficacy endpoints like OS, PFS, etc.; (3) The trial phase is not specified, and it is not clearly a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial. PMID 40504479 · J Cancer Surviv · 2025-Jun-12 The study is an oncology, human, randomized controlled trial with original results, but it is excluded because it evaluates a non-drug intervention (nurse-led follow-up program) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. PMID 40504283 · J Neurol · 2025-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. PMID 40500695 · Mol Cancer · 2025-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Home-based online exercise training and chronic, low-grade inflammation in cancer patients after curative surgery: secondary analysis of the randomized controlled multicenter CRBP-TS trial. PMID 40498221 · Support Care Cancer · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lung cancer screening in Finland: a prospective randomized trial. PMID 40497290 · Acta Oncol · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Non-randomised prospective clinical trial to improve follow-up adherence, survivorship knowledge and late effects documentation at a childhood cancer clinic in Western Kenya: a study protocol. PMID 40499965 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical effect of ePRO-based symptom monitoring and management on improving survival outcomes in patients with advanced cancer: a single-centre, prospective, randomised controlled trial protocol. PMID 40499961 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The effect of supportive care on mood, general health, competence on caregivers of cancer patients, and supportive care needs on cancer patients undergoing chemotherapy: a controlled clinical trial. PMID 40493212 · Support Care Cancer · 2025-Jun-10 The study is a randomized controlled trial in oncology (cancer patients undergoing chemotherapy). However, the intervention is a 'supportive care program' (psychosocial/nursing), not a drug-containing intervention (the chemotherapy is routine, not the intervention under study). The endpoints are quality-of-life, caregiver burden, and supportive care needs (PROs), not time-to-event efficacy endpoints (OS, PFS, etc.). It is also not a Phase III/IIIb or Phase II/III trial (no phase specified).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation. PMID 40388602 · J Gerontol A Biol Sci Med Sci · 2025-Jun-10 The record describes an observational cohort study (target trial emulation) comparing metformin versus sulfonylureas for longevity in women with type 2 diabetes. It is not an oncology study, not a randomized trial, and not a Phase III or Phase II/III randomized trial with a drug intervention for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. PMID 40294366 · J Clin Oncol · 2025-Jun-10 The record describes a cross-study analysis comparing outcomes of hematopoietic stem cell transplantation (HSCT) versus chemotherapy alone in pediatric high-risk AML patients. While it references Phase III trials and reports DFS (time-to-event), it does not meet all inclusion criteria. Specifically, it is not a primary report of a single randomized trial; it is a secondary analysis combining data from two trials. More critically, the intervention of interest is HSCT (a procedure), not a drug-containing intervention. The comparison involves chemotherapy, but the focus is on the transplant procedure. The randomization status for the specific comparison in this analysis is also not explicitly established in the abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. PMID 40249893 · J Clin Oncol · 2025-Jun-10 The study is a randomized Phase III trial in oncology with a drug intervention (concurrent chemotherapy) and reports an original result. However, it does not meet the primary requirement of having a time-to-event efficacy endpoint (like OS or PFS) as the primary or key secondary outcome. The abstract explicitly reports only early toxicity within 6 months, which is a safety endpoint, not an efficacy endpoint with time-to-event characteristics (e.g., Kaplan-Meier, HR). Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study). PMID 40184561 · J Clin Oncol · 2025-Jun-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. PMID 40460847 · Lancet · 2025-Jun-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study. PMID 40481437 · BMC Med · 2025-Jun-06 The record describes an oncology randomized trial with a drug intervention and time-to-event endpoints. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, or publication types). The 'deterministic_review' signal 'phase3: false' indicates this criterion cannot be confirmed. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. PMID 40473437 · BMJ · 2025-Jun-05 Meets all eligibility criteria: oncology human RCT with drug intervention, Phase II/III trial (NCT05631262, open-label randomised controlled trial), primary and secondary time-to-event efficacy endpoints (PFS, OS) with HR results, and original trial result report. Phase is not explicitly labeled as 'III' in metadata but trial design and registration indicate definitive Phase II/III.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Enhancing postoperative recovery in robotic-assisted prostatectomy: a randomized trial of LEARNS model, auricular acupressure, and intestinal rehabilitation. PMID 40471457 · J Robot Surg · 2025-Jun-05 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis. PMID 40468999 · Acta Oncol · 2025-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. PMID 40542585 · Oncologist · 2025-Jun-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy. PMID 40488582 · J Crohns Colitis · 2025-Jun-04 The record describes a non-oncology disease (ulcerative colitis) and does not report a primary/key secondary time-to-event efficacy endpoint for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial. PMID 40468382 · Trials · 2025-Jun-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized controlled trial exploring the effect of placement versus nonplacement of a drainage tube around the cervical anastomosis in McKeown esophagectomy. PMID 40467612 · Sci Rep · 2025-Jun-04 The trial is a surgical RCT without a drug intervention and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Consensus process to agree upon surgical quality assurance processes within a pragmatic, multicentre randomised clinical trial comparing targeted axillary dissection and axillary node clearance: the TADPOLE-TOGETHER project. PMID 40461151 · BMJ Open · 2025-Jun-03 The record is a protocol for a surgical randomized controlled trial in oncology (breast cancer), but it does not report results of a drug-containing intervention with a time-to-event efficacy endpoint. The intervention is surgical, and the publication is a protocol describing a quality assurance process, not an original result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial. PMID 40311506 · Eur J Cancer · 2025-Jun-03 The study is a phase III, randomized, oncology, human, drug-intervention trial with original results. However, it is ineligible because the prespecified efficacy endpoints are response rates (categorical outcomes), not time-to-event outcomes as required by the cohort definition.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. PMID 40306121 · Eur J Cancer · 2025-Jun-03 The record describes a pooled analysis of two prior Phase III trials, evaluating a prognostic factor (relative dose intensity). It is not the primary or secondary result report of a single randomized trial. The intervention (FOLFOXIRI vs. doublets) was randomized in the parent trials, but this analysis is a post-hoc/prognostic subgroup analysis, not the original trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial. PMID 40279684 · Eur J Cancer · 2025-Jun-03 The record describes a randomized, drug-intervention trial in advanced melanoma reporting time-to-event efficacy outcomes (PFS, OS), but the provided metadata does not explicitly confirm it as a Phase III/IIIb or Phase II/III trial. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Randomized Control Trial of Two Interventions Compared with Usual Care for Increasing Cervical Cancer Screening among Women Living in the Rural Midwest. PMID 40197927 · Cancer Epidemiol Biomarkers Prev · 2025-Jun-03 The study is an oncology-related randomized trial, but it does not meet the key eligibility criteria: it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not involve a drug-containing intervention (comparing a DVD/patient navigation intervention vs. usual care).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -